A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Seborrhoeic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 02 Oct 2014 Primary endpoint has been met (physicians subjective assessment of the condition of the lesion, assessed on the Physician Lesion Assessment Scale), according to an Aclaris Therapeutics media release.
    • 02 Oct 2014 Results published in an Aclaris Therapeutics media release.
    • 11 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top